Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
226.00
+1.97 (0.88%)
Oct 26, 2026, 9:38 AM EDT - Market open
Alnylam Pharmaceuticals Revenue
Alnylam Pharmaceuticals had revenue of $1.29B in the quarter ending June 30, 2026, with 66.86% growth. This brings the company's total for the last twelve months to $4.80B, up 95.14% year-over-year. In the year 2025, Alnylam Pharmaceuticals had annual revenue of $3.71B with 65.19% growth. That makes Alnylam Pharmaceuticals the 2,695th largest company in the world by revenue and 775th in the United States.
Revenue (ttm)
$4.80B
Revenue Growth
+95.14%
P/S Ratio
6.24
Revenue / Employee
$1,921,673
Employees
2,500
Market Cap
30.24B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Alnylam Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.71B | 1.47B | 65.19% |
| Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
| Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
| Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
| Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
| Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
| Dec 31, 2019 | 219.75M | 144.84M | 193.36% |
| Dec 31, 2018 | 74.91M | -15.00M | -16.69% |
| Dec 31, 2017 | 89.91M | 42.75M | 90.66% |
| Dec 31, 2016 | 47.16M | 6.06M | 14.75% |
| Dec 31, 2015 | 41.10M | -9.46M | -18.72% |
| Dec 31, 2014 | 50.56M | 3.39M | 7.20% |
| Dec 31, 2013 | 47.17M | -19.56M | -29.31% |
| Dec 31, 2012 | 66.73M | -16.03M | -19.37% |
| Dec 31, 2011 | 82.76M | -17.28M | -17.28% |
| Dec 31, 2010 | 100.04M | -492.00K | -0.49% |
| Dec 31, 2009 | 100.53M | 4.37M | 4.54% |
| Dec 31, 2008 | 96.16M | 45.27M | 88.94% |
| Dec 31, 2007 | 50.90M | 23.97M | 89.00% |
| Dec 31, 2006 | 26.93M | 21.21M | 371.13% |
| Dec 31, 2005 | 5.72M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| argenx SE | 5.92B |
| Incyte | 5.82B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Exelixis | 2.44B |
| Ascendis Pharma | 1.20B |
ALNY News
- 3 days ago - Alnylam reports ALN-HTT02 clinical trial results - TheFly
- 3 days ago - Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease - Business Wire
- 11 days ago - Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results - Business Wire
- 11 days ago - Alnylam assumed with a Buy at UBS - TheFly
- 12 days ago - Alnylam price target lowered to $253 from $256 at Wells Fargo - TheFly
- 12 days ago - Alnylam price target lowered to $320 from $340 at Citi - TheFly
- 17 days ago - Alnylam price target lowered to $336 from $346 at BofA - TheFly
- 18 days ago - Alnylam price target lowered to $345 from $350 at RBC Capital - TheFly